+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.

Age: 18Years +All GendersPhase 3
224 locations
R

Actively Recruiting

Researchers are evaluating the use of one versus multiple arterial grafts in patients undergoing primary isolated non-emergency coronary artery bypass surgery CABG. This international, randomized trial aims to determine if multiple arterial grafts reduce a combined outcome of death, stroke, heart attack after discharge, or repeat revascularization, compared to a single arterial graft. The study also seeks to assess if multiple arterial grafts improve overall survival in these patients with coronary artery disease. Participants are randomly assigned to receive either a single arterial graft, which is the left internal thoracic artery plus venous grafts, or multiple arterial grafts including the left internal thoracic artery plus a second arterial graft such as the right internal thoracic artery or radial artery. Some patients in the multiple graft group may receive additional arterial grafts. This trial enrolls at least 4,300 patients across 25 international centers and uses a 11 randomization with stratification by center and graft type. During the study, participants will be monitored for outcomes including death, stroke, myocardial infarction, and repeat revascularization starting more than 72 hours after surgery. Additional assessments include 30-day mortality, postoperative complications, sternal wound healing, and hospital readmissions. Follow-up analyses will evaluate survival and cause-specific mortality over an average of 5 years. The study is expected to continue until 2030, with comprehensive safety and effectiveness monitoring throughout.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
59 locations